President and CEO, OncoGenex Pharmaceuticals
I began my career with an interest in medicine and pharmaceutical sciences. In considering going into post-secondary education,
I was introduced to a small biotech company pursuing immune modulation. I spoke with the company and was offered a position.
The rest, as they say, is history.
Later, I cofounded OncoGenex with Martin Gleave. Since then, I've led OncoGenex through significant corporate milestones,
including serial rounds of private financing, and taken the corporation from preclinical through completion of multiple Phase
II clinical trials.
I believe in pursuing novel therapeutics to materially change disease management. OncoGenex's product pipeline is comprised
of a majority of product candidates designed to inhibit novel targets. The company's randomized Phase II data in prostate
cancer, which showed a 40 percent reduction in the rate of death compared to the gold standard therapy, demonstrates the success
of this approach.